Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FRTXNASDAQ:GNPXNASDAQ:GTBPNASDAQ:NBSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFRTXFresh Tracks Therapeutics$0.94-0.5%$0.94$0.03▼$1.03$5.59M0.542,709 shs2,402 shsGNPXGenprex$0.30+6.0%$0.28$0.22▼$4.09$7.76M-0.43.82 million shs386,657 shsGTBPGT Biopharma$2.82-0.7%$2.36$1.72▼$4.10$7.29M1.48349,625 shs20,284 shsNBSENeuBase Therapeutics$0.38$0.38$0.36▼$4.80$1.43MN/AN/AN/A7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFRTXFresh Tracks Therapeutics0.00%0.00%0.00%-0.53%+8.71%GNPXGenprex+3.28%+0.72%-3.41%-25.31%-86.79%GTBPGT Biopharma-1.73%+6.77%+23.48%+23.48%-19.55%NBSENeuBase Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGNPXGenprex2.1492 of 5 stars0.04.00.04.72.80.01.3GTBPGT Biopharma3.5614 of 5 stars3.85.00.00.03.30.81.3NBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFRTXFresh Tracks Therapeutics 0.00N/AN/AN/AGNPXGenprex 0.00N/AN/AN/AGTBPGT Biopharma 3.50Strong Buy$11.00290.07% UpsideNBSENeuBase Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFRTXFresh Tracks Therapeutics$10.06M0.56N/AN/A$1.66 per share0.56GNPXGenprexN/AN/AN/AN/A$4.99 per shareN/AGTBPGT BiopharmaN/AN/AN/AN/A$5.42 per shareN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/AN/AN/AN/AN/AGNPXGenprex-$30.86MN/A0.00N/AN/AN/A-409.48%-269.17%8/8/2025 (Estimated)GTBPGT Biopharma-$7.60M-$5.69N/AN/AN/AN/A-257.47%-131.09%8/13/2025 (Estimated)NBSENeuBase Therapeutics-$4.37MN/A0.00∞N/AN/AN/AN/AN/ALatest NBSE, FRTX, GTBP, and GNPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GTBPGT Biopharma-$0.64-$0.76-$0.12-$0.33N/AN/A5/12/2025Q1 2025GNPXGenprex-$0.82-$0.26+$0.56-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFRTXFresh Tracks TherapeuticsN/AN/AN/AGNPXGenprexN/A0.860.86GTBPGT BiopharmaN/A1.451.45NBSENeuBase TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFRTXFresh Tracks Therapeutics25.04%GNPXGenprex14.05%GTBPGT Biopharma8.15%NBSENeuBase Therapeutics12.37%Insider OwnershipCompanyInsider OwnershipFRTXFresh Tracks Therapeutics0.23%GNPXGenprex8.47%GTBPGT Biopharma10.90%NBSENeuBase Therapeutics7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFRTXFresh Tracks Therapeutics205.97 million5.96 millionNot OptionableGNPXGenprex2027.82 million7.79 millionNo DataGTBPGT Biopharma82.59 million1.99 millionNo DataNBSENeuBase Therapeutics403.75 million3.46 millionNot OptionableNBSE, FRTX, GTBP, and GNPX HeadlinesRecent News About These CompaniesGreenlight Capital Q3 2024 LetterOctober 17, 2024 | seekingalpha.comNeuBase Therapeutics shareholder meeting adjourns without dissolution approvalMay 13, 2024 | bizjournals.comNeuBase Therapeutics to delist from Nasdaq next weekMay 6, 2024 | bizjournals.comNeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from NasdaqApril 6, 2024 | finanznachrichten.deNeuBase Therapeutics Announces Receipt of Notice from NasdaqApril 5, 2024 | globenewswire.comOnce-promising Pittsburgh biotech firm shutting down for goodMarch 27, 2024 | technical.lyWhy Neubase Therapeutics (NBSE) Shares Are NosedivingMarch 27, 2024 | msn.comNeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare moversMarch 26, 2024 | msn.comWhy Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?March 26, 2024 | investorplace.comNeuBase Therapeutics sets shareholder meeting on dissolution planMarch 25, 2024 | bizjournals.comNeuBase Therapeutics IncFebruary 26, 2024 | edition.cnn.comNeuBase Therapeutics, Inc. (NBSE)February 20, 2024 | finance.yahoo.comNeuBase Therapeutics Inc (O7P.BE)January 20, 2024 | ca.finance.yahoo.comMonitoring NeuBase Therapeutics Inc (NBSE) after recent insider movementsJanuary 1, 2024 | knoxdaily.comCMU halts licensing agreement with NeuBase TherapeuticsDecember 22, 2023 | bizjournals.comPsychemedics Corporation Appoints Daniella Mehalik as VP - FinanceNovember 27, 2023 | finance.yahoo.comNeuBase Therapeutics Inc NBSENovember 6, 2023 | morningstar.comNeuBase Therapeutics: Other EventsOctober 21, 2023 | cbonds.comNeuBase Therapeutics, Inc. (NBSE.MX)October 6, 2023 | finance.yahoo.comNeuBase Therapeutics Inc. (NBSE) gets rating Reiterated from H.C. WainwrightSeptember 20, 2023 | knoxdaily.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBSE, FRTX, GTBP, and GNPX Company DescriptionsFresh Tracks Therapeutics NASDAQ:FRTX$0.94 -0.01 (-0.53%) As of 02/28/2025Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.Genprex NASDAQ:GNPX$0.30 +0.02 (+6.03%) As of 11:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.GT Biopharma NASDAQ:GTBP$2.82 -0.02 (-0.70%) As of 11:44 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.NeuBase Therapeutics NASDAQ:NBSENeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? CrowdStrike Stock Slips: Analyst Downgrades Before Earnings AutoZone Stock to Cross $4400 This Year: This Is Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
